144 related articles for article (PubMed ID: 29599373)
1. Clinicopathological Profiling of LC3B, an Autophagy Marker, and ESRRA (Estrogen-related Receptor-alpha) in Muscle-invasive Bladder Cancer.
Kim S; Lee AJ; Yeo MK; Na YG; Kim JY; Cho MJ; Kim JS; Jo EK; Kim JM
Anticancer Res; 2018 Apr; 38(4):2429-2437. PubMed ID: 29599373
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
[TBL] [Abstract][Full Text] [Related]
3. The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Chen S; Jiang YZ; Huang L; Zhou RJ; Yu KD; Liu Y; Shao ZM
Clin Cancer Res; 2013 Dec; 19(24):6853-62. PubMed ID: 24141623
[TBL] [Abstract][Full Text] [Related]
4. Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.
Mortezavi A; Salemi S; Rupp NJ; Rüschoff JH; Hermanns T; Poyet C; Randazzo M; Simon HU; Moch H; Sulser T; Wild P; Eberli D
Oncotarget; 2017 May; 8(19):31765-31774. PubMed ID: 28423666
[TBL] [Abstract][Full Text] [Related]
5. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
[TBL] [Abstract][Full Text] [Related]
6. Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer.
Silvers CR; Liu YR; Wu CH; Miyamoto H; Messing EM; Lee YF
Oncotarget; 2016 Apr; 7(17):23335-45. PubMed ID: 26981774
[TBL] [Abstract][Full Text] [Related]
7. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.
Wu CT; Lin WY; Chen WC; Chen MF
Ann Surg Oncol; 2018 Nov; 25(12):3518-3526. PubMed ID: 30128900
[TBL] [Abstract][Full Text] [Related]
8. Analysis of HSP27 and the Autophagy Marker LC3B
Livingston JA; Wang WL; Tsai JW; Lazar AJ; Leung CH; Lin H; Advani S; Daw N; Santiago-O'Farrill J; Hollomon M; Gordon NB; Kleinerman ES
Mol Cancer Ther; 2018 Jun; 17(6):1315-1323. PubMed ID: 29592877
[TBL] [Abstract][Full Text] [Related]
9. High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer.
Nitschke K; Worst TS; von Rhade SM; Thaqi B; Neuberger M; Wessels F; Weis CA; Porubsky S; Gaiser T; Kriegmair M; von Hardenberg J; Weidenbusch M; Erben P; Nuhn P
Urol Oncol; 2021 Aug; 39(8):499.e1-499.e8. PubMed ID: 34134925
[TBL] [Abstract][Full Text] [Related]
10. Utility of SAM68 in the progression and prognosis for bladder cancer.
Zhang Z; Yu C; Li Y; Jiang L; Zhou F
BMC Cancer; 2015 May; 15():364. PubMed ID: 25944080
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas.
Adams O; Dislich B; Berezowska S; Schläfli AM; Seiler CA; Kröll D; Tschan MP; Langer R
Oncotarget; 2016 Jun; 7(26):39241-39255. PubMed ID: 27250034
[TBL] [Abstract][Full Text] [Related]
12. Combination of ULK1 and LC3B improve prognosis assessment of hepatocellular carcinoma.
Wu DH; Wang TT; Ruan DY; Li X; Chen ZH; Wen JY; Lin Q; Ma XK; Wu XY; Jia CC
Biomed Pharmacother; 2018 Jan; 97():195-202. PubMed ID: 29091866
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.
Worst TS; Weis CA; Stöhr R; Bertz S; Eckstein M; Otto W; Breyer J; Hartmann A; Bolenz C; Wirtz RM; Erben P
Sci Rep; 2018 Sep; 8(1):14383. PubMed ID: 30258198
[TBL] [Abstract][Full Text] [Related]
14. Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2.
Kim YH; Kim WT; Jeong P; Ha YS; Kang HW; Yun SJ; Moon SK; Choi YH; Kim IY; Kim WJ
J Korean Med Sci; 2014 Mar; 29(3):351-6. PubMed ID: 24616583
[TBL] [Abstract][Full Text] [Related]
15. Significance of CLASP2 expression in prognosis for muscle-invasive bladder cancer patients: A propensity score-based analysis.
Chen L; Xiong W; Guo W; Su S; Qi L; Zhu B; Mo M; Jiang H; Li Y
Urol Oncol; 2019 Oct; 37(10):800-807. PubMed ID: 31130343
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival.
Xu Z; Yu YQ; Ge YZ; Zhu JG; Zhu M; Zhao YC; Xu LW; Yang XB; Geng LG; Dou QL; Jia RP
Tumour Biol; 2015 Sep; 36(10):8159-66. PubMed ID: 25990459
[TBL] [Abstract][Full Text] [Related]
17. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of LC3B and p62/SQSTM1 Expression in Gastric Adenocarcinoma.
Kim JS; Bae GE; Kim KH; Lee SI; Chung C; Lee D; Lee TH; Kwon IS; Yeo MK
Anticancer Res; 2019 Dec; 39(12):6711-6722. PubMed ID: 31810936
[TBL] [Abstract][Full Text] [Related]
19. SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.
Keck B; Wach S; Goebell PJ; Kunath F; Bertz S; Lehmann J; Stöckle M; Taubert H; Wullich B; Hartmann A
Ann Surg Oncol; 2013 Oct; 20(11):3669-74. PubMed ID: 23807662
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
